Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1816 to 1830 of 2185 results for guidelines

  1. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Withdrawn advice

  2. Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  3. Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  4. Type 2 diabetes: lixisenatide (ESNM26)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Withdrawn advice

  5. Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  6. Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  7. Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  8. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Withdrawn advice

  9. Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  10. Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  11. Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

    This evidence summary has been updated and replaced by NICE guideline NG203.

    Withdrawn advice

  12. Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  13. Asthma: tiotropium (Spiriva Respimat) (ESNM55)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  14. Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  15. Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice